Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice.

[1]  Peter Nash,et al.  Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial , 2006, The Lancet.

[2]  J. Falck,et al.  Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. , 2005, Cardiovascular research.

[3]  G. Ertl,et al.  Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the α‐glucosidase inhibitor acarbose , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  M. Hori,et al.  Cerebral ischemia in 5-lipoxygenase knockout mice , 2004, Brain Research.

[5]  N. Patel,et al.  The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. , 2004, Cardiovascular research.

[6]  P. Galuppo,et al.  Peroxisome proliferator activated‐receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction , 2004, British journal of pharmacology.

[7]  S. Cuzzocrea,et al.  5-Lipoxygenase Knockout Mice Exhibit a Resistance to Splanchnic Artery Occlusion Shock , 2003, Shock.

[8]  K. Welt,et al.  Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury? An ultrastructural-morphometric study. , 2000, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[9]  M. Singh,et al.  Role of eicosanoid inhibition of ischemia reperfusion injury: intact and isolated rat heart studies. , 1997, Methods and findings in experimental and clinical pharmacology.

[10]  B. Koller,et al.  Altered inflammatory responses in leukotriene-deficient mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Funk,et al.  Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene , 1994, Nature.

[12]  J. Salmon,et al.  Selective 5‐Lipoxygenase Inhibitor BW A4C Does Not Influence Progression of Tissue Injury in a Canine Model of Regional Myocardial Ischaemia and Reperfusion , 1991, Journal of cardiovascular pharmacology.

[13]  P. J. Simpson,et al.  Antagonism of leukotriene B4 receptors does not limit canine myocardial infarct size. , 1990, The Journal of pharmacology and experimental therapeutics.

[14]  M. Katori,et al.  Detection of leukotriene B4 in cardiac tissue and its role in infarct extension through leucocyte migration. , 1988, Cardiovascular research.

[15]  K. Mullane,et al.  Myocardial Salvage Induced by REV‐5901: An Inhibitor and Antagonist of the Leukotrienes , 1987, Journal of cardiovascular pharmacology.

[16]  V. Fiedler,et al.  Effects of Nafazatrom and Indomethacin on Experimental Myocardial Ischemia in the Anesthetized Dog , 1985, Journal of cardiovascular pharmacology.

[17]  M. Bednar,et al.  Nafazatrom‐Induced Salvage of Ischemic Myocardium in Anesthetized Dogs is Mediated through Inhibition of Neutrophil Function , 1985, Circulation research.

[18]  B. Samuelsson.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. , 1983, Science.

[19]  M. Schork,et al.  Reduction of the Extent of Ischemic Myocardial Injury by Neutrophil Depletion in the Dog , 1983, Circulation.

[20]  G. Gross,et al.  Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. , 2007, Prostaglandins & other lipid mediators.

[21]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[22]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.

[23]  A. Ford-hutchinson.  Leukotriene B4 in inflammation. , 1990, Critical reviews in immunology.